Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Ginkgo Bioworks Holdings Inc’s stock clocked out at $0.99, up 3.47% from its previous closing price of $0.95. In other words, the price has increased by $3.47 from its previous closing price. On the day, 30.72 million shares were traded. DNA stock price reached its highest trading level at $1.03 during the session, while it also had its lowest trading level at $0.961.
Ratios:
To gain a deeper understanding of DNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.11 and its Current Ratio is at 6.11. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 14, 2023, Downgraded its rating to Mkt Perform and sets its target price to $2.50 from $3.50 previously.
Goldman Downgraded its Neutral to Sell on June 02, 2023, whereas the target price for the stock was revised from $3 to $1.25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 02 ’24 when Coen Steven P. sold 131,928 shares for $0.84 per share. The transaction valued at 111,479 led to the insider holds 162,527 shares of the business.
Dmytruk Mark E. sold 47,806 shares of DNA for $40,396 on May 02 ’24. The insider now owns 925,400 shares after completing the transaction at $0.84 per share. On Apr 02 ’24, another insider, Dmytruk Mark E., who serves as the insider of the company, sold 51,169 shares for $1.05 each. As a result, the insider received 53,727 and left with 865,079 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 2103684736 and an Enterprise Value of 1275675392. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.18 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 5.073 whereas that against EBITDA is -1.926.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $0.74. The 50-Day Moving Average of the stock is -9.20%, while the 200-Day Moving Average is calculated to be -34.33%.
Shares Statistics:
It appears that DNA traded 30.11M shares on average per day over the past three months and 62932910 shares per day over the past ten days. A total of 1.53B shares are outstanding, with a floating share count of 1.39B. Insiders hold about 33.29% of the company’s shares, while institutions hold 56.49% stake in the company. Shares short for DNA as of 1713139200 were 266527056 with a Short Ratio of 8.85, compared to 1710460800 on 262237448. Therefore, it implies a Short% of Shares Outstanding of 266527056 and a Short% of Float of 21.78.
